In the SURPASS-4 randomized clinical trial, a post-hoc analysis showed that tirzepatide, when compared to insulin glargine, decreased the progression of albuminuria and the rate of decline in estimated glomerular filtration rate (eGFR), ultimately reducing by nearly half the risk of a predefined composite renal outcome, including a 40% eGFR…[Leer más]